Pyrazinamide-induced maculopapular rash

Indian Journal of Dermatology

Volumn 55, Issue 4, 2010, Pages 384-386

  Khayyam, Khalid Umer ^a   Imam, Faisal ^b   Sharma, Manju ^b   Pillai, K K ^b   Behera, D ^a  

^a Lala Ram Sarup Inst TB All Dis   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Maculopappular rash; naranjo and hartwig scales; pyrazinamide

Indexed keywords

ANTIHISTAMINIC AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ALGORITHM; ARTICLE; CASE REPORT; DRUG TOLERABILITY; HUMAN; LUNG TUBERCULOSIS; MACULOPAPULAR RASH; MALE; QUESTIONNAIRE; THORAX RADIOGRAPHY;

EID: 78651291933     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.74562     Document Type: Article

References (10)

1. Fernandez TD, Mayorga C, Torres MJ, Cornejo-Garcia JA, López S, Chaves P, et al. Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs. Allergy 2008;63:712-9.
2. Elias A, Madhusoodanan S, Pudukkadan D, Antony JT. Angioedema and maculopapular eruptions associated with carbamazepine administration. CNS Spectr 2006;11:352-4.
3. Mehta DK, Martin J, Costello I, Jordan B, editors. BNF 50; London: BMJ publishing group; 2005.
4. Managing the Revised National Tuberculosis Programme inyour area: A Training Course. Module 1-4.Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare, Nirman Bhavan. 2005. p. 76-110.
5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)
6. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32.
7. Magee P. Drug-induced skin disorders. In: Walker R, Edwards C, editors. Clinical Pharmacy and Therapeutics. 3rd edi. Phildelphia: Churchill Livingstone; 2003. P. 843-52.
8. Bolognia JL, Braverman IM. Skin manifestations of internal disease. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrisons Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001. p. 315-31.
9. Perdu D, Lavaud F, Prévost A, Deschamps F, Cambie MP, Bongrain E, et al. Erythema multiforme due to pyrazinamide. Allergy 1996;51:340-42.
10. Horn DL, Hewlett DJ, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994;330:1241.